Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Safety and Efficacy Study of Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis

NCT02701205 is registered in ClinicalTrials.gov with Shanghai Celgen Bio-Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT02701205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02701205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Safety and Efficacy Study of Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis
Lead sponsor
Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2015
Completion date
December 31, 2017
Enrollment
216 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, psoriasis